Acitretin

證據等級: L5

預測適應症: 4 個

Acitretin: From Psoriasis to Acne (Disease)

One-Sentence Summary

Acitretin is a second-generation aromatic retinoid, primarily used for severe psoriasis and other keratinization disorders. The TxGNN model predicts it may be effective for acne (disease), with 1 clinical trial and 18 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Psoriasis and keratinization disorders (per literature context; NPRA approved indication text not available in current dataset)
Predicted New Indication	Acne (disease)
TxGNN Prediction Score	99.94%
Evidence Level	L3
Malaysia Market Status	✓ Marketed
Number of Registrations	4
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Acitretin is a second-generation aromatic retinoid that acts as a full agonist of retinoic acid receptors (RAR-α, RAR-β, and RAR-γ). Through nuclear receptor signalling, it regulates keratinocyte differentiation, inhibits sebaceous gland activity (sebosuppression), and modulates inflammatory pathways including leukotriene production and NF-κB activity. Detailed MOA data from DrugBank was not available in this dataset, but the mechanistic framework is well-characterised in the dermatological literature.

Acne pathogenesis is driven by three overlapping mechanisms that retinoids directly target: follicular hyperkeratinisation, excessive sebaceous gland secretion, and local inflammation. A closely related molecule, isotretinoin (13-cis retinoic acid), is already the established first-line treatment for severe nodulocystic acne. Acitretin belongs to the same pharmacological class and shares sebosuppressive and anti-inflammatory mechanisms, though it differs in pharmacokinetic profile and teratogenic risk classification.

Case reports have documented acitretin’s use in nodulocystic acne and hidradenitis suppurativa (acne inversa), a chronic inflammatory disorder mechanistically and anatomically related to acne. Long-term follow-up data from a 25-year case series (PMID 20874789) further supports the biological plausibility of the TxGNN prediction, positioning acitretin as a mechanistically coherent, if pharmacologically second-choice, retinoid candidate for acne management.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04663906	N/A	Unknown	300	Observational study examining whether oral retinoid-induced nasal mucosal dryness increases COVID-19 infection risk. Study subject is isotretinoin (not acitretin); indirectly indicates systemic retinoid use in the acne population is under active safety scrutiny. No efficacy data for acitretin.

Note: No clinical trials directly evaluating acitretin for acne were identified. The sole trial retrieved concerns a related retinoid (isotretinoin) and addresses a safety question, not treatment efficacy.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
20874789	2011	Case Series / Retrospective	Br J Dermatol	25-year experience with acitretin for hidradenitis suppurativa (acne inversa); demonstrates clinically meaningful long-term responses and questions whether HS is truly a misnomer for acne inversa
12080949	2002	Case Report	Cutis	Patient with severe nodulocystic facial acne and HS treated with acitretin after two isotretinoin courses; partial clinical improvement noted in persistent facial cysts
25640693	2015	Clinical Guideline	J Eur Acad Dermatol Venereol	European S1 guideline for HS/acne inversa; includes retinoids (including acitretin) within recommended treatment options
28476075	2017	Cochrane Review	Cochrane Database Syst Rev	Systematic review of drug treatments for discoid lupus erythematosus; evaluates retinoids as a treatment class, providing high-level evidence context for acitretin’s immunomodulatory and skin-normalising effects
41692081	2026	Narrative Review	Clin Dermatol	Comprehensive update on vitamin A and retinoids in dermatology; explicitly covers acitretin alongside isotretinoin for acne-related and keratinisation disorders
8573927	1995	Review / Mechanistic	Dermatology (Basel)	Examines retinoid-mediated inhibition of sebaceous gland activity; establishes the mechanistic basis for predicting anti-acne effects across the retinoid class, including acitretin
29234829	2018	Review	Der Hautarzt	Review of pharmacological treatments for acne inversa; positions retinoids including acitretin within the treatment landscape alongside antibiotics and TNF-α inhibitors
9074840	1997	Narrative Review	Drugs	Broad review of retinoid indications in dermatology; describes acitretin’s established role in psoriasis and discusses applicability to acne-related dermatoses
2112772	1990	Mechanistic (In Vitro)	Prostaglandins	Demonstrates that acitretin inhibits eosinophil leukotriene C4 (LTC4) production; supports anti-inflammatory mechanism relevant to acne-associated tissue inflammation
1617858	1992	PK / Efficacy Review	Clin Pharmacokinet	Pharmacokinetic comparison of retinoids; confirms acitretin’s established efficacy for psoriasis and hyperkeratosis, and discusses PK differences versus isotretinoin that are relevant to acne use

Malaysia Market Information

Four product registrations for acitretin are recorded with the NPRA (market status: Marketed). However, detailed licence information — including authorisation numbers, product names, dosage forms, and approved indication text — was not available in the current dataset. Please verify directly via the NPRA online portal (https://www.npra.gov.my) for complete registration details.

Authorization Number	Product Name	Dosage Form	Approved Indication
(Not available in dataset)	—	—	—

Safety Considerations

Please refer to the package insert for safety information.

Important note: Safety data including key warnings, contraindications, and drug interaction information were not retrievable in this dataset (Data Gap DG001). Given that acitretin carries FDA Pregnancy Category X status and is associated with teratogenicity, hepatotoxicity, and hypertriglyceridaemia, reviewing the official NPRA-approved package insert before any clinical or regulatory decision is essential.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Acitretin shares the core retinoid mechanism of action with isotretinoin — an established first-line treatment for severe acne — and case series and observational data support its use in acne-related disorders such as hidradenitis suppurativa. The L3 evidence base (no RCTs; supported by case reports, guidelines, and mechanistic reviews) justifies cautious advancement rather than outright rejection, but direct efficacy data for acitretin specifically in acne vulgaris is currently absent.

To proceed, the following is needed:

Safety data retrieval (Priority: Blocking): Download and parse the NPRA-approved package insert to extract key warnings, contraindications, and pregnancy risk information before any clinical assessment
MOA confirmation: Query DrugBank API (DB00459) to retrieve structured mechanism of action data for regulatory dossier use
Differentiation analysis: Clarify the clinical niche for acitretin vs. isotretinoin in acne — particularly for patients where isotretinoin is contraindicated or has failed
Comparative PK/safety review: Document the teratogenicity and hepatotoxicity profile differences between acitretin and isotretinoin to assess feasibility in target populations
Prospective study design: Consider a pilot observational study or structured case series for acitretin in acne inversa/nodulocystic acne where isotretinoin has been inadequate, to generate Tier 2 evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.